Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?

John Thomas Helgstrand, Kasper Drimer Berg, Solvej Lippert, Klaus Brasso, Martin Andreas Røder

    13 Citations (Scopus)


    Objective Primary androgen deprivation therapy (ADT) remains the gold standard in the management of patients with advanced prostate cancer (PCa). ADT relieves symptoms and reduces tumor burden, but it has never been demonstrated to increase either PCa-specific or overall survival per se. Several trials have challenged this dogma. The aim of this study was to evaluate how endocrine therapy (ET) affects survival in different clinical settings of PCa. Materials and methods A review of published phase II, III and IV studies evaluating the effect of ET on survival was performed. Results In localized and locally advanced non-metastatic PCa, neoadjuvant ET before radical prostatectomy has no effect on survival. Neoadjuvant and adjuvant ET in combination with curatively intended radiotherapy results in PCa-specific and overall survival benefit, although the duration of ET remains under debate. In N + disease, the timing of ET is under debate, although data suggest that early ET is associated with decreased PCa-specific and overall mortality. In M + disease, no proper randomized trials have been performed in patients with newly diagnosed M1 disease. In metastatic castration-resistant PCa, two novel endocrine agents have been proven to increase overall survival significantly compared to placebo. Conclusions ET has never been proven to increase survival in newly diagnosed metastatic PCa in a randomized clinical trial. Nonetheless, a number of trials supports that ET with proper timing, sequencing and in combination with other therapeutic modalities increases survival in several stages of PCa.

    Original languageEnglish
    JournalScandinavian Journal of Urology and Nephrology
    Issue number3
    Pages (from-to)135-43
    Number of pages9
    Publication statusPublished - Jun 2016


    Dive into the research topics of 'Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?'. Together they form a unique fingerprint.

    Cite this